Bulk Quote Inquiry

CD1-HM119F-100μg / Inquiry

CD1-HM119F-500μg / Inquiry

CD1-HM119F-1mg / Inquiry

FITC-Compatible Human CD19 Protein

Product Info

FITC-Compatible Human CD19 Protein is expressed from Expi293 with His tag at the C-terminal. It contains Pro20-Lys291.[Accession | P15391-1]

Molecular Weight

The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Supplied as 0.22μm filtered solution in PBS (pH 7.4).


The product should be stored at -70℃. Please do not repeated freeze-thaw cycles.

Assay Data
Tris-Bis PAGE

FITC-Compatible Human CD19 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.


The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC.


Use Human CD19-FITC Compatible protein to detect the expression rate of Anti-CD19-CAR positive cells. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.


CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.


B4;CVID3;B-lymphocyte antigen CD19


(1) Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. PMID: 30784102.

Kactus Biosystems Co.Ltd
Online Message